These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 30466690)

  • 1. Updates in Melanoma.
    Tracey EH; Vij A
    Dermatol Clin; 2019 Jan; 37(1):73-82. PubMed ID: 30466690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapies for Advanced Melanoma.
    Bomar L; Senithilnathan A; Ahn C
    Dermatol Clin; 2019 Oct; 37(4):409-423. PubMed ID: 31466582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considering adjuvant therapy for stage II melanoma.
    Poklepovic AS; Luke JJ
    Cancer; 2020 Mar; 126(6):1166-1174. PubMed ID: 31869447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Metastatic Melanoma in 2018.
    Kaufman HL; Margolin K; Sullivan R
    JAMA Oncol; 2018 Jun; 4(6):857-858. PubMed ID: 29621376
    [No Abstract]   [Full Text] [Related]  

  • 5. Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy.
    Queirolo P; Boutros A; Tanda E; Spagnolo F; Quaglino P
    Semin Cancer Biol; 2019 Dec; 59():290-297. PubMed ID: 31430555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
    Lim SY; Menzies AM; Rizos H
    Cancer; 2017 Jun; 123(S11):2118-2129. PubMed ID: 28543695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced Melanoma: Current Treatment Options, Biomarkers, and Future Perspectives.
    Rozeman EA; Dekker TJA; Haanen JBAG; Blank CU
    Am J Clin Dermatol; 2018 Jun; 19(3):303-317. PubMed ID: 29164492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma Patient Outcome Prediction Tool with a 31-gene expression profile-based classification.
    Ferris LK; Farberg AS; Middlebrook B; Johnson CE; Lassen N; Oelschlager KM; Maetzold DJ; Cook RW; Rigel DS; Gerami P
    J Am Acad Dermatol; 2017 May; 76(5):818-825.e3. PubMed ID: 28110997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises.
    Bhave P; Haydon A
    Australas J Dermatol; 2020 Aug; 61(3):203-209. PubMed ID: 32403192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to PD-1 blockade in melanoma.
    Burki TK
    Lancet Oncol; 2016 Sep; 17(9):e376. PubMed ID: 27452143
    [No Abstract]   [Full Text] [Related]  

  • 11. Lessons learned from the Sunbelt Melanoma Trial.
    McMasters KM; Noyes RD; Reintgen DS; Goydos JS; Beitsch PD; Davidson BS; Sussman JJ; Gershenwald JE; Ross MI;
    J Surg Oncol; 2004 Jul; 86(4):212-23. PubMed ID: 15221928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients.
    Hao H; Xiao D; Pan J; Qu J; Egger M; Waigel S; Sanders MA; Zacharias W; Rai SN; McMasters KM
    Ann Surg Oncol; 2017 Jan; 24(1):108-116. PubMed ID: 27663566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Checkpoint Inhibitors in Kidney Transplant Recipients and the Potential Risk of Rejection.
    Alhamad T; Venkatachalam K; Linette GP; Brennan DC
    Am J Transplant; 2016 Apr; 16(4):1332-3. PubMed ID: 26752406
    [No Abstract]   [Full Text] [Related]  

  • 14. A Population-based Study of Survival Impact of New Targeted and Immune-based Therapies for Metastatic or Unresectable Melanoma.
    Hanna TP; Nguyen P; Baetz T; Booth CM; Eisenhauer E
    Clin Oncol (R Coll Radiol); 2018 Oct; 30(10):609-617. PubMed ID: 30196844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in melanoma staging and therapy.
    McMasters KM; Sondak VK; Lotze MT; Ross MI
    Ann Surg Oncol; 1999; 6(5):467-75. PubMed ID: 10458685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of metastatic malignant melanoma: on the way to individualized disease control.
    Vogt T
    Adv Exp Med Biol; 2014; 810():272-81. PubMed ID: 25207371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of initial recurrence and prognosis after sentinel lymph node biopsy and selective lymphadenectomy for melanoma.
    Wagner JD; Ranieri J; Evdokimow DZ; Logan T; Chuang TY; Johnson CS; Jung SH; Wenck S; Coleman JJ
    Plast Reconstr Surg; 2003 Aug; 112(2):486-97. PubMed ID: 12900606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of melanoma therapy: developing new drugs and improving the use of old ones.
    Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V
    Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206
    [No Abstract]   [Full Text] [Related]  

  • 19. MicroRNAs that predict the effectiveness of anti-PD-1 therapies in patients with advanced melanoma.
    Nakahara S; Fukushima S; Okada E; Morinaga J; Kubo Y; Tokuzumi A; Matsumoto S; Tsuruta-Kadohisa M; Kimura T; Kuriyama H; Miyashita A; Kajihara I; Jinnin M; Ihn H
    J Dermatol Sci; 2020 Jan; 97(1):77-79. PubMed ID: 31843231
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
    Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
    Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.